Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. results from a large retrospective family cohort study

Haematologica

Volumn 95, Issue 6, 2010, Pages 1030-1033

  Mäkelburg, Anja B U ^a   Veeger, Nic J G M ^a   Middeldorp, Saskia ^c   Hamulyák, Karly ^d   Prins, Martin H ^d   Büller, Harry R ^b   Lijfering, Willem M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carriers; Deep vein thrombosis; Factor V leiden; Paradox; Pulmonary embolism; References

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE CARRIER; FAMILY STUDY; FEMALE; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; RELATIVE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; THROMBOPHILIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FACTOR V; FEMALE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; PEDIGREE; POINT MUTATION; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 77953184314     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.017061     Document Type: Article

References (19)

1. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232(2):155-60.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med. 1992;152(8):1660-4.
3. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692-9.
4. Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an un - selected population of patients with pul-monary embolism. Lancet. 1996;347(9012): 1374-5.
5. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pul-monary embolism. Lancet. 2000;356(9225): 182-3.
6. Martinelli I, Cattaneo M, Panzeri D, Mannucci PM. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost. 1997; 77(3): 440-3.
7. Turkstra F, Karemaker R, Kuijer PM, Prins MH, Büller HR. Is the prevalence of the factor V Leiden mutation in patients with pul-monary embolism and deep vein thrombosis really different? Thromb Haemost. 1999;81(3):345-8.
8. Meyer G, Emmerich J, Helley D, Arnaud E, Nicaud V, Alhenc-Gelas M, et al. Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med. 2001; 110 (1):12-5.
9. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thrombo - embolism. Thromb Haemost. 2001;86(3): 809-16.
10. van Stralen KJ, Doggen CJ, Bezemer ID, Pomp ER, Lisman T, Rosendaal FR. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol. 2008; 28(10):1872-7.
11. Kuismanen K, Savontaus ML, Kozlov A, Vuorio AF, Sajantila A. Coagulation factor V Leiden mutation in sudden fatal pul-monary embolism and in a general northern European population sample. Forensic Sci Int. 1999;106(2):71-5.
12. Vandenbroucke JP, Bertina RM, Holmes ZR, Spaargaren C, van Krieken JH, Manten B, et al. Factor V Leiden and fatal pulmonary embolism. Thromb Haemost 1998; 79(3):511-6.
13. Bank I, Libourel EJ, Middeldorp S, van Pampus EC, Koopman MM, Hamulyak K, et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. 2004;164(17): 1932-7.
14. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus EC, Koopman MM, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005;3(1):79-84.
15. Brouwer JL, Veeger NJ, van der Schaaf W, Kluin-Nelemans JC, van der Meer J. Differ ence in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol. 2005;128(5): 703-10.
16. Brouwer JL, Veeger NJ, Kluin-Nelemans JC, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med. 2006;145(11):807-15.
17. Lijfering WM, Coppens M, van de Poel MH, Middeldorp S, Hamulyak K, Bank I, et al. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost. 2007; 98(2):457-63.
18. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol. 1996; 143(12):1257-65.
19. Büller HR, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6(8):1313-8.